3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
67
Triple Negative Breast Neoplasms
16
Neoplasm Metastasis
9
Sarcoma
6
Ovarian Neoplasms
4
Brain Neoplasms
4
Neoplasms
3
Liposarcoma
3
Inflammatory Breast Neoplasms
3
HER2-negative Breast Cancer
3
Leiomyosarcoma
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Salivary Gland Neoplasms
1
Relapsed Solid Tumors
1
Refractory Solid Tumors
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Metastatic Urothelial Cell Cancer
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Ketosis
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
HER2-negative Metastatic Breast Cancer
1
Interventions
Fulvestrant
6
olaparib
4
Letrozole
4
trastuzumab deruxtecan
3
Aromatase Inhibitors
3
Anastrozole
3
sacituzumab govitecan
2
pyrotinib
2
eribulin
2
dalpiciclib
2
Paclitaxel
2
Goserelin
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Capecitabine
2
toripalimab
1
talazoparib
1
sonidegib
1
ribociclib
1
pembrolizumab
1
neratinib
1
liposomal doxorubicin
1
elacestrant
1
disitamab vedotin
1
ceralasertib
1
capivasertib
1
balixafortide
1
apatinib
1
abemaciclib
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Breast Cancer
×
eribulin
×
Clear all
NCT05530057
2025-11-20
ESPERO
Seoul National University Hospital
Phase 2
Recruiting
180 enrolled
NCT04826016
2023-03-20
POLTER
MedSIR
Phase 1/2
Withdrawn